Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by CytoDyn Inc.
December 2024 Letter to Shareholders
December 17, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
November 25, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
November 04, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
October 30, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
October 08, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
October 07, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
October 04, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
September 24, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
September 2024 Letter to Shareholders
September 09, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
August 23, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
August 12, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Settlement with Amarex Clinical Research LLC
July 09, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
June 27, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn to Host Webcast to Provide Company Update
May 28, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
May 2024 Letter to Shareholders
May 16, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces FDA Has Lifted Clinical Hold
February 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
February 01, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
January 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Webcast to Provide Company Update
December 07, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
November 21, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
November 2023 Letter to Shareholders
November 03, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Company Updates and Investment Community Update Webcast
July 11, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces President Takes Medical Leave of Absence
May 24, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
December 23, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
November 22, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
October 28, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Appointment of Additional Directors with Industry Experience
October 20, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
Tickers
CYDY
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
January 25, 2022
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
January 13, 2022
From
CytoDyn Inc.
Via
Business Wire
Tickers
CYDY
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.